Join collection
Hello, welcome to our official website!
互联网保险需要三思而后行
2019-01-12

  2018年可能成为我国互联网保险发展的一个“关口”,或是一个“转折”,因此,“今非昔比”既是状态,更应是心态,在这个历史背景下,互联网保险*需要的是“三思而后行”,不仅是回顾历史的反思与总结,更是面向未来的清晰与坚定。


  我国互联网保险经过了十几年的发展,取得的成绩可谓是有目共睹,但与此同时也面临着许多突出问题和深层次矛盾,尤其是2016年以来,互联网保险的发展出现了较大的“跌宕起伏”。于是,有人困惑,也有人疑惑,更有人批评,甚至是指责。但殊不知,任何一个新生事物的成长都会面临“跌宕起伏”,甚至是“磕磕碰碰”,这既是成长的代价,更是发展的必然。

  2018年可能成为我国互联网保险发展的一个“关口”,或是一个“转折”,因此,“今非昔比”既是状态,更应是心态。在这个历史背景下,互联网保险*需要的是“三思而后行”,不仅是回顾历史的反思与总结,更是面向未来的清晰与坚定。

  回顾历史,我国互联网保险在推动保险业改革、创新与发展过程中发挥了重要和独特的作用,可以用三句话概括,一是异军突起,作用显著。作为一种新生力量,互联网保险不仅是提高了效率,更创造了可能,解决了许多发展、改革和服务中的“瓶颈”和“*后一公里”问题,推动了行业的创新与进步,可谓是作用显著,功不可没。二是各美其美,相得益彰。在互联网保险的发展过程中,不仅有传统的保险企业,也有互联网保险企业。不仅有保险企业,也有互联网保险科技企业,还有互联网科创企业。他们相互协同,交相辉映,取长补短,共同创新。三是科技赋能,重塑保险。互联网保险*大贡献在于科技赋能,通过对时空的再认识与利用,变不可能为现实,不仅是结构性降低了运营成本,更解决了经营过程中的风险、信用和效率等难题,实现了商业模式的迭代,同时,实现了碎片化和场景化的创新。

  这是一个快速变化的时代,快的让人有点“猝不及防”,就来不及“思”,更没有时间“想”。没有了思想,缺乏了理论,淡漠了文化,就难免冲动、盲目、浮躁,乃至“任性”。都说“这个世界**不变的就是变化”,于是,人们就忙于“变化”,殚精竭虑,身心俱疲,蓦然回首,却迷茫于“我是谁”。但在中国古人看来,世界是变的,世界更是不变的。人,只有把握好不变的,才能够把握未来。中国人称这种“不变”为“常”,为“道”。 有的时候,人们觉得“道”是一个玄乎其玄的东西,一个远在天边的东西。殊不知,当你觉悟了,“道”就在你的眼前身边。把握好“道”是为人处世的根本和基础,因为,古人说:得道者,得天下。

  互联网保险面临自我迭代的挑战,这种挑战,不单是技术,也不仅是商业,而是思想、理论、理念与文化。因为,离开理论的实践,注定是盲目的实践。因为,一支没有文化的军队,注定是要打败战的。互联网保险是要探索一条“前无古人”的路,没有“前车之鉴”,靠什么指引方向,靠理论,靠文化。要做到这一点,就需要不断地反思,正如孔子在听说季文子每每做事均“三思而后行”时说:再,斯可矣,讲的是借鉴以往的重要。无论是“思”,还是“再”,其本质均是“省”,因此,古人说:吾日三省吾身。在互联网保险的发展过程中,尤其需要不断地回顾、反思和检讨,需要不断的“三思”和“三省”,继而问道于心,明心见性,且行且珍惜。

  “三思”的第一“思”是回答“为什么”,即为什么做互联网保险。

  “为什么”的背后是“为了谁”,即发展互联网保险的宗旨问题。这个问题看似简单,但却经不起“推敲”。今天,从事互联网保险的人可谓是来自“五湖四海”,但并非都是为了一个“共同的目标”走到一起。相信大多数人肯定是为了理想而来,但也不乏个别“心怀叵测”的投机者,想的是“赶时髦”、“炒概念”,然后“套现走人”。人们为什么而来,即为什么做互联网保险,或者是为了谁做互联网保险,似乎已成为了所有问题的“结”。提出这个问题,是因为有些人也许太忙了,并没有认真“思”过这个问题,稀里糊涂地就来做互联网保险,就难免做的稀里糊涂。当然,或许有些人也想过,却“难以启齿”,或“不可告人”。

  中国古人推崇:修身齐家治国平天下。纵观互联网保险的发展过程,特别是出现的乱象和存在的问题,症结就出在“修身”。而“修身”的关键是回答:为什么。这既是问题所在,也是成功的关键。“为什么”的问题回答好了,就不容易出问题,就能够成功。所以,每一个做互联网保险的人,首先要解决好“修身”与“齐家(公司)”的问题,即“为什么”和“为了谁”的问题,因为,这是你的出发,你的初心,是你“行走于江湖”的依靠与寄托。如果根本和基础问题解决不好,那么,离成功就可能“相去甚远”,更别谈什么“治国”与“平天下”。

  作为一种互联网平台,流量肯定是“意义非凡”,因为,得流量者,得天下。作为一家公司,故事很重要,投资者买的就是“故事”。作为一个创业团队,资本更是重要,没有了资本青睐,再好的理想抱负,也只能是想想而已。虽然流量、故事和资本都重要,而且很重要,但它们肯定不是互联网保险的根本和全部。互联网保险*重要的是发挥自身的特点和优势,提**率,创造可能,而更重要的是为客户创造价值,福祉行业和社会。

  这些年,互联网保险,特别是互联网车险,“井喷式”发展是它,“塌陷式”下滑也是它,让外人看的是“一头雾水”,局中人则“心知肚明”。从表面上看,都是“15%”惹的祸,但从根本上讲,仍是跳不出“掩耳盗铃”和“自欺欺人”的局限,忘记了心存敬畏是做人做事的根本道理。

  明白大道理并不难,难的是知行合一,难的是先后顺序。传统文化中有“己欲立而立人,己欲达而达人”的智慧,讲的是先人后己,成人达己。无论是保险,还是互联网保险,都面临这个问题,即是先成人,还是先达己。许多时候,人们更多地是想“达己”,结果往往是事与愿违,欲速不达。佛家讲:渡人渡己。把别人渡到了彼岸,蓦然回首,你已然在彼岸。互联网保险的发展*需要的就是这种智慧,而*缺的也是这种智慧。

  “三思”的第二“思”是回答“是什么”,即互联网保险到底是什么。

  古人说:凡事预则立,不预则废。这句话的后面还有一段:言前定则不跲,事前定则不困,行前定则不疚,道前定则不穷。讲的是说话办事,尤其是办大事之前,务必先把一些根本性的问题想清楚,弄明白。就互联网保险而言,也面临这个问题,互联网保险到底是什么,是渠道,是营销手段,还是商业模式。这些问题如果还没有想清楚,弄明白,在做的过程中就可能面临困惑、纠结,乃至迷茫。

  随着互联网保险公司的出现,作为一种商业模式,似乎已是不言而喻了。但互联网保险公司的出现并不等于互联网保险商业模式的成熟,它只是为探索互联网保险商业模式提供了一种“机缘”,因此,什么是互联网保险,什么是互联网保险的基础理论、基本原理,互联网保险发展的基本逻辑是什么,互联网保险的核心能力是什么,它的商业模式是什么,诸如此类,林林总总的问题仍有待人们回答,特别是通过实践去回答。古人说:君子务本,本立道生。互联网保险也一样,上述问题均属于互联网保险的根本性问题,如果这些问题回答不好,就可能找不到自己的“初心”,就容易“本末倒置”,“忘乎所以”,甚至是“舍本逐末”,“误把他乡做故乡”,就不可能做好互联网保险。

  “三思”的第三“思”是回答“做什么”,即互联网保险做什么。

  互联网保险,属于“前无古人”的事业,因此,需要“摸着石头过河”,在战争中学习战争,在不断的探索与实践中回答互联网保险是什么的问题。当下有一个观点经常被滥用,就是“试错”。积极实践,大胆探索固然重要,但所有的实践与探索均应当是理性的,应当在理论的指导下开展的,否则就是盲目,甚至是愚昧。就互联网保险而言,可以肯定的是:并不是所有的保险产品均适合互联网经营模式的。互联网保险也面临“有所为有所不为”的问题。更重要的是:互联网保险有其独特的优势,但这些优势也需要“善加利用”。现在有些互联网保险业务是建立在保险业发展过程中存在的“问题”基础上,比如“借个道”、“开张票”和“垫点钱”,尽管也能够实现“商业模式”,甚至赚得“盆满钵满”,但肯定不是互联网保险发展的“正道”,还可能“误了卿卿性命”。因此,互联网保险的发展,需要回答的往往不是能够做什么,而是应该做什么。

  互联网发展到了今天,尤其是在商业领域的应用,发挥的作用,取得的成绩是有目共睹的,并形成了独特的“商业模式”,但其中的许多做法,仍有待时间检验。但就互联网保险而言,则“又当别论”,作为一种金融制度安排,保险具有很强的特殊性,因此,不能简单地“拥抱”互联网,可以肯定:不是所有互联网的“成功经验”均适合互联网保险经营,这就是古人讲“南橘北枳”的道理。面对互联网,保险需要“知己知彼”,需要“因地制宜”,更要清晰并坚守自我。*重要的是不能照搬照抄,更不能盲目跟风,赶时髦,要有所取舍,扬长避短,为我所用,定义并打造互联网保险的技术和商业模式。

  在互联网保险的发展过程中,往往容易陷入互联网行业的“集体亢奋”状态。“亢奋”不是一件坏事,做事业,尤其是做一番前无古人的大事业,热情和激情均是必不可少的。但保险是一种平滑机制,不能太“跌宕起伏”,更不能“心惊肉跳”。因此,“淡定”很重要。保险需要日积月累,不能太“急功近利”,更懂得“敬畏时间”。因此,“定力”很重要。同时,要记得:能够成就大事业的重要前提是“不忘初心”,做互联网保险,*重要的是不能忘记“我是谁”。互联网保险,“互联网”是形容词,“保险”是主语,因此,互联网保险还是保险,切莫“数典忘祖”。

  射悻合同的特征决定了保险具有一定“虚”的成分,而互联网的“虚”是不言而喻的,两个“虚”相遇,决定了互联网保险注定要面对一场虚实观的挑战。无论是保险,还是商业,信用均是基础、灵魂和命根子。要知道:虚则不实,不实则不信,因此,如何将互联网保险做“实”,无疑是一个难题,但又是无法回避的。都说只要思想不滑坡,办法总是比困难多,因此,解决思想认识问题是基础,是关键,清晰、坚定并践行正确的互联网保险虚实观是重要路径。韩非子曾经说过:存亡在虚实,不在众寡。这句话,对盲目地沉迷于“流量”的人们无疑是一副清醒剂,更是给了互联网保险虚实观以启迪。做互联网保险的人应明白:做实难,做实也不难,难的是“诚实心意”。

  互联网保险的基本属性决定了科技,尤其是科技创新能力至关重要,因此,加大投入也就势在必行。但问题的关键不是要不要投入,而是如何投入,回答如何投入的前提是回答为什么投入。当下让人有点忧心忡忡的是:不知道从什么时候开始,“烧钱”成为了一种流行,甚至是时髦。在老百姓看来,钱,是不能拿来“烧”的,太可惜了,也犯法。钱,是用来花的,花钱过日子。“烧钱”,那是“烧”给死人的。咋一听,有点“风马牛不相及”,仔细想想,个中道理,似乎也相通。

  科技创新的本质是提**率,创造价值。风险投资的本意是为了通过一种制度安排,有效分散风险,激励创新探索,为社会创造价值。但任何事情均有个度,“度”的这边是鼓励探索,“度”的那边是纵容盲目,甚至“居心叵测”。因此,要高度关注社会层面的科技创新总绩效问题,科学和理性应当成为社会创新文化的重要内涵。

  创新和创业都不容易。正是不易,更要心存敬畏,不能任性。不是有句话说:出来混,都是要还的。创业者更要有一份清醒,有的时候,你烧的不仅是投资者的钱,还有自己的大好时光和机会。

  流量是互联网经济的起点,也是关键,所以有了那句话:流量为王。因此,所有的竞争均围绕引流展开,与此同时,也孕育了独特的商业模式。从互联网保险发展的情况看,引流成本,或业务获取成本畸高是一个不争的现实,又是一种“无能为力”的无奈。

  从表面看,这种高额“买路钱”的背后,是行业缺乏自身的销售能力,缺乏自己的渠道,因此,不得不仰仗于人,受制于人。同时,行业内部的恶性竞争,相互厮杀,也是导致这种结果的重要原因和推手。但从根本看,在当今互联网社会,保险公司,尤其是中小保险公司是难以与那些大型的互联网门户抗衡的。因此,需要从社会公平的角度看问题。中国的商业伦理讲的是:君子爱财,取之有道。而互联网门户,依仗自身的市场势力,漫天要价,强取豪夺,严重侵害了社会公共利益,要知道,这种高额的“买路钱”*终还是要由消费者和社会买单的,显然,这种“商业模式”与“道”是渐行渐远,乃至背道而驰,应当引起全社会的高度关注。值得注意的是这种互联网“商业模式”已经导致了线上成本甚至高于线下成本的问题,这无疑是饮鸩止渴,乃至是自掘坟墓。

  在中国,做保险本不容易,在互联网上做保险就更不容易。但正是因为“不容易”,就要更加珍惜,更加诚信。近来,有些“网红”的健康保险产品,采用了“全免”的承保政策,引发“爆款”效应。但问题的关键是“宽进”能否“宽出”?如果一开始就预谋着“宽进严出”,那么,诚信何在,天理何在。古人说:己所不欲勿施于人,况且谁都不傻,如果非要这么做,终究要付出更大的代价。此外,一些“大手笔”的优惠措施,是否有科学,特别是数据依据,能否守约,能否持久,也值得质疑。一时吸引眼球固然刺激,但日子还需要慢慢过,保险更是这样。也许有人说,亏钱没关系,反正烧的是VC的钱,但VC的钱总有烧完的一天,重要的是“没有了钱烧”的日子怎么过。更让人担忧的是,一阵风过后,VC还是昨天的VC,你已不是从前的你。

  互联网保险是需要发展,但更需要理性发展;业务需要增长,但必须是有益增长,而不是有害增长。任何时代,总有些人比较任性,但这种“任性”的后果往往是要社会和行业买单的,因此,发展互联网保险,作为个体,切莫“不管不顾”,作为行业,对少数人的“不管不顾”,不能视而不见,听之任之。

  纵观人类社会发展的历史,所有的进化,包括了技术、制度和社会,乃至大千世界,均遵循着遗传、突变和选择的规律,互联网保险也不可能例外。发展互联网保险,首先,是把握根本,即回答并坚守保险的根本,解决好“传承”问题。其次,是善于创新,即实现创新发展,特别是本质创新,解决好“突变”问题。第三,是不忘初心,即要做到万变不离其宗,取舍自如,这种“选择”的本质是道法自然。

  互联网保险是个新概念,发展互联网保险更需要传统文化的滋养。中国古人说:人能弘道,非到弘人。在互联网保险的发展过程中,“主语”是人,包括企业、行业和客户,即是靠人去弘互联网的道,而不是由互联网来弘人,这个“道”就是利用互联网技术更好地为客户提供服务,为社会创造福祉,为行业谋求发展。就互联网保险而言,什么是自己的“道”,真的要好好想想,切莫辜负时代。

  要“弘道”,关键是要“厚德”,“厚德”方可“载物”。要“弘道”,更需要“行深”,“行深”才能“致远”。面向未来,中国保险业,也包括互联网保险可谓是:任重道远。走好未来的路,远见卓识,开疆拓土固然重要,但集体共识,克己复礼,厚德载物,道行天下更重要。

保险学者,中国人保财险执行副总裁

转自新浪财经

暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Gotham Therapeutics Establishes Advanced Oncology Profiling Cascade with ProQinase to Progress its Portfolio of Epitranscriptomic Drug CandidatesWEDNESDAY, OCTOBER 30, 2019Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ProQinase, an early stage drug-discovery company, recently acquired by Malvern/PA-based Reaction Biology Corp., today announced that they have established an array of advanced biochemical and cellular assays to characterize epitranscriptomic-directed compounds.“Establishing tailored target engagement, cell biology, phenotypic, and in-vivo assays to evaluate compounds originating from our three most advanced epitranscriptomic programs in parallel is a crucial next step to develop our broad pipeline towards the clinic,” said Dr. Gerhard Müller, Chief Scientific Officer of Gotham Therapeutics. “By pursuing the full range of the reader-writer-eraser continuum, we are able to focus on targets with the most compelling links to disease and advance those programs in tandem.”“Combining our high proficiency in providing customized solutions as early stage drug-discovery services, including tailor-made biochemical and cell-based assays, with Gotham’s expertise in epitranscriptomics, we were able to establish in a very short time a set of customized enzymatic and cellular assays for compounds addressing three different mRNA-modifying targets,” said Dr. Sebastian Dempe, Chief Executive Officer of ProQinase. “We look forward to supporting Gotham as the company advances its programs into lead optimization and to continued work with the Gotham team assisting the company to advance its broad pipeline in a time-effective manner.”In addition to establishing a tailor-made profiling cascade for compounds from its three most advanced programs, Gotham has also made progress in strengthening its drug discovery engine and developing its candidate base. Gotham previously completed the gene-to-lead phase for its drug discovery project targeting the METTL3/METTL14 complex and established a robust discovery process as a platform for future projects. The company has also generated a library of high-quality compounds tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space. This library includes a collection of over 2,000 analogues covering over 80 distinct chemotypes that will be used to further accelerate Gotham’s drug discovery efforts as it expands its pipeline.The original link:https://www.pharmafocusasia.com/news/gotham-therapeutics-establishes-advanced-oncology-profiling-cascade-with-proqinase-to-progress-its-portfolio-of-epitranscriptomic-drug-candidates2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical DevelopmentTUESDAY, OCTOBER 29, 2019Gilead Sciences Inc. and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”information source:pharma focus AsiaThe original link:https:https:https://www.pharmafocusasia.com/news/gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development2019 Asia-pacific pharma IP Leader Summit:http://en.zenseegroup.com/p/510934/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology PlatformMONDAY, OCTOBER 28, 2019HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible data on therapeutic responses in NASH animal models, and to aid CROs as well as research agencies in validating new models mimicking the NASH disease.Published preclinical studies have demonstrated the use of HistoIndex's fully quantifiable Second Harmonic Generation (SHG) technology as a highly accurate stain-free method that can monitor the efficacy of various therapeutic agents, by quantifying more than 450 NASH-associated parameters in fibrosis, inflammation, ballooning and steatosis. The information of these NASH-associated parameters gathered from the entire liver tissue, provides comprehensive insights on the mechanism of action of the therapeutic agent.  As a drug discovery tool, HistoIndex's SHG-enabled digital pathology platform will allow pharmaceutical and biotech companies to select promising lead candidates for further optimization and make informed decisions in the management of their NASH drug development pipeline.In addition to ongoing NASH clinical trials, HistoIndex is currently involved in multiple preclinical studies, most of which are conducted by major pharmaceutical and biotech companies, medical universities, CROs and research agencies. Notably, HistoIndex has recently entered into a collaboration with the A*STAR's Genome Institute of Singapore (GIS) to validate their in vivo and in vitro NASH models based on Asian-centric clinical data. Says Professor Patrick Tan, Executive Director of the Genome Institute of Singapore (GIS), "At GIS, we conduct our preclinical studies on fatty liver involving data from animal models based on patient-derived transcriptomic data. This has a high translational potential as it helps us to pinpoint new therapeutic targets and their validation. Therefore, using a fully quantitative, reliable and objective pathological evaluation such as HistoIndex's AI-based digital pathology platform is essential to the success of our efforts in therapeutic target discovery."HistoIndex is also a partner with globally-renowned CRO, WuXi Apptec, in advancing their NASH preclinical programs with advanced R&D and smart imaging analysis capabilities. Published study data will be available for discussions during networking opportunities throughout AASLD's The Liver Meeting® in November 2019.  "We are very excited to extend our AI-based SHG platform to preclinical studies to help companies with drug discovery programs select promising lead candidates for further optimization and subsequent clinical development," says Dr Poon Thong Yuen, Chief Executive Officer of HistoIndex. "Our SHG image analysis platform has already been used to analyze the efficacy of a series of promising drug candidates for NASH within various animal models commonly-used by the industry, and we believe these preclinical partnerships will help drive the adoption of our platform significantly."information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/histoindex-announces-global-partnerships-to-expand-ai-based-digital-pathology-platform2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher DiseaseFRIDAY, OCTOBER 25, 2019AVROBIO, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease. AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. The Company is actively recruiting in Canada for its Phase 1/2 clinical trial of AVR-RD-02, which seeks to evaluate the safety and efficacy of the therapy in patients with Type 1 Gaucher disease.“Under the existing standard of care, patients with Gaucher disease are bound to a lifelong infusion schedule of enzyme replacement therapies, and still experience painful and progressive symptoms such as debilitating musculoskeletal pain and fatigue,” said Birgitte Volck, MD, PhD, President of Research and Development at AVROBIO. “Orphan-drug designation recognizes the unmet need of populations with rare diseases like Gaucher where AVROBIO strives to transform lives by addressing the underlying cause of the disease with a single dose of gene therapy.”Orphan-drug designation is granted by the FDA to drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. Orphan-drug designation provides certain incentives, which may include tax credits towards the cost of clinical trials and prescription drug user fee waivers.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/avrobio-receives-orphan-drug-designation-from-the-us-fda-for-avrrd02-for-the-treatment-of-gaucher-disease2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the acquisition of Smith Therapeutics, a private biopharmaceutical company with a shared goal of targeting neuroinflammation to treat neurodegenerative disease. Smith Therapeutics’ Founder and Chief Executive Officer Philip Ashton-Rickardt, Ph.D., has joined the senior leadership team at AZTherapies as Senior Vice President of Immunology. Financial terms of the acquisition were not disclosed.Smith Therapeutics’ proprietary research platform focuses on the use of modified T cells to restore a healthy balance of inflammatory and regulatory cells in the brain. To date, Smith has successfully engineered immunosuppressive T regulatory (Treg) cells with Chimeric Antigen Receptors (CARs) targeting brain glial cells. Previous research has demonstrated the ability of Tregs to dampen microglial activity and reduce neuroinflammation in models of neurodegeneration, suggesting their potential utility in the treatment of diseases including Progressive Supranuclear Palsy (PSP), Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and others.“This acquisition represents a meaningful step forward for us as we continue to strengthen our leadership position in the development of therapies targeting neuroinflammation to stop or slow the progression of neurodegenerative diseases,” said David R. Elmaleh, Ph.D., Founder, CEO, and Chairman of AZTherapies. “We are excited to be working with Philip as we add this cutting-edge technology to our portfolio of innovative programs. An esteemed immunologist and inventor of the technology, Philip brings unparalleled expertise to the company and we look forward to advancing this CAR-Treg program further into IND-enabling studies and into clinical development as rapidly as possible.”Dr. Ashton-Rickardt commented on the acquisition and his appointment: “Our shared rationale of targeting neuroinflammation as the root cause of neurodegenerative disease makes this acquisition a great strategic fit for us. With AZTherapies’ expertise in drug development and clinical trial execution, we believe that together, we are well positioned to advance our CAR-Treg technology and fundamentally change neurodegenerative disease progression.”Prior to launching Smith Therapeutics in 2017, Dr. Ashton-Rickardt was Chair in Immunology at Imperial College London, Visiting Professor, Brigham and Women’s Hospital, Harvard Medical School, and Associate Professor in the Department of Pathology at the University of Chicago. His work has been recognized by his peers through the award of tenure from The University of Chicago and by his fellow citizens as a recipient of the Early Career Award for Scientists and Engineers from President Bill Clinton. He has published more than 65 peer-reviewed papers in more than 30 academic journals (including Cell, Science, Immunity, and Nature Immunology), has served as an editor for several academic journals, and has been a member of grant review boards globally. Dr. Ashton-Rickardt received a B.Sc. in Biochemistry from the University of London, King’s College with honors, a Ph.D. in Molecular Biology from the University of Edinburgh, and completed post-doctoral work at the University of Edinburgh and the Massachusetts Institute of Technology in Molecular Biology and Molecular Immunology, respectively.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/aztherapies-strengthens-neuroinflammation-targeted-pipeline-through-acquisition-of-smith-therapeutics2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

About Us
Contact Us
Zensee_Daystar online